(RDY) Shares Trading up at $31.18 Dr. Reddy’s (RDY) Alert: J&W…


Dr. Reddy’s Laboratories Ltd (NYSE:RDY):

Dr. Reddy’s (RDY) Alert: J&W Investigates Dr. Reddy’s Laboratories Ltd.; Has Your Dr. Reddy’s Investment Declined in Value?.

The company is trading up by 2.80 percent from yesterday’s close.

Dr. Reddy’s Laboratories Ltd declared a dividend for shareholders that was paid on Thu Aug 10, 2017. The dividend was $0.078 per share for the quarter or $0.31 on an annualized basis. This dividend amount was represent a yeild of $0.97. The ex-dividend date was Thursday the 13th of July 2017.

Dr. Reddy’s Laboratories Limited, launched on February 24, 1984, is a pharmaceutical company that is involved in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Business’s business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities (NCEs). These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC. Others include the operations of its subsidiary, Aurigene Discovery Technologies Limited, a discovery-stage biotechnology company developing therapies in the fields of oncology and inflammation..

Company shares last traded at $31.18 which is significantly lower than the 50 day moving average of $39.33 and significantly lower than the 200 day moving average of $41.03. The 50 day moving average was down $-8.15 and the 200 day average was down $-9.85.

The company currently has a P/E ratio of 29.17 and market cap is 5.17B.